The unique history of Wilson Sonsini Goodrich & Rosati closely traces the birth and evolution of Silicon Valley.
For more than 60 years, Wilson Sonsini has represented technology pioneers associated with virtually every milestone innovation, as well as life sciences trailblazers shaping the future of healthcare.
Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.
Careers
We look for the best and brightest of tomorrow and develop careers from the ground up.
News and Featured Insights
Leading Matters
Client Highlights
Firm Advises Khartis Therapeutics on Patent Matters Related to $50 Million Series B
On August 13, 2026, Khartis Therapeutics, a biotechnology company developing both first- and best-in-class oral small molecule medicines for immunological and chronic diseases, announced that it has raised $50 million in Series B financing. The round was led by Forge Life Science Partners, with participation from Longwood Fund and Alexandria Venture Investments, alongside existing investors Foresite Capital, Lilly Asia Ventures, and Nextech Invest, bringing total capital raised to $95 million. Wilson Sonsini Goodrich & Rosati advised Khartis on patent matters related to the transaction and has served as patent counsel for the company since its inception in 2024.
Client Highlights
Wilson Sonsini Advises Vals AI on $40 Million Series A led by Andreessen Horowitz
On Thursday, August 13, 2026, Vals AI, an AI evaluation platform, announced the completion of a $40 million Series A financing, valuing the company at $400 million. Andreessen Horowitz led the round, with participation from existing investors 8VC, Pear VC, and Bloomberg, and new investors Hudson River Trading and NextLadder Ventures. Wilson Sonsini Goodrich & Rosati advised Vals AI on the transaction.
Client Highlights
Wilson Sonsini Advises Pathway on Seed Funding Round
On August 11, 2026, Pathway, a frontier lab building architectures and models that has created post-transformer models, announced additional funding at a $500 million valuation. The new capital brings the company's total seed financing to $30 million and will be used to increase compute capacity. The round included Id4 Ventures, TQ Ventures, Red Bridge Ventures, Kadmos Capital, WS Investment Co., the investment arm of Wilson Sonsini, and angel investor Jonathan Frankle, Chief AI Scientist at Databricks. Wilson Sonsini advised Pathway on the transaction.
Client Highlights
California Supreme Court Expands Access to Electronic Court Recording in Wilson Sonsini Litigation
On August 10, 2026, the California Supreme Court issued a unanimous opinion in Family Violence Appellate Project v. Superior Court, No. S288176, expanding access to electronic recording of trial court hearings when no court reporter is available. The court’s opinion recognized that a verbatim record of court proceedings can be essential to access to justice and that electronic recording represents an effective technology for meeting that need, particularly for indigent parties who cannot afford to hire a court reporter. The decision further expands upon access to electronic recording provided in general orders enacted by trial courts around the state.
Client Highlights
Wilson Sonsini Advises Cylinder Health on $105 Million Acquisition by Hinge Health
On August 4, 2026, Hinge Health, a digital healthcare company, announced that it has signed a definitive agreement to acquire Cylinder Health, a leader in virtual-first digestive healthcare, for $105 million in cash consideration. Wilson Sonsini Goodrich & Rosati advised Cylinder Health on the transaction.
Client Highlights
Firm Advises Braveheart Bio on Patent Matters Related to $382.5 Million IPO
On August 5, 2026, Braveheart Bio, a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, announced the pricing of its upsized initial public offering of 21,250,000 shares of its common stock at a public offering price of $18.00 per share. The gross proceeds from the initial public offering, before deducting underwriting discounts and commissions and other offering expenses payable by Braveheart Bio, are expected to be $382.5 million, excluding any exercise of the underwriters’ option to purchase additional shares of common stock. Wilson Sonsini Goodrich & Rosati advised Braveheart Bio on patent matters related to the transaction.
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025.